Research programme: ligand activated therapeutics - KemPharm

Drug Profile

Research programme: ligand activated therapeutics - KemPharm

Alternative Names: KP 214; KP 515; KP 606; KP 612; KP 746; KP303; KP606/IR; KP7xx

Latest Information Update: 06 Mar 2014

Price : $50

At a glance

  • Originator KemPharm
  • Class Dibenzothiazepines; Morphine derivatives; Opioid peptides; Phenylacetates; Piperazines; Piperidines; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Dopamine release stimulants; Opioid receptor agonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute pain; Attention-deficit hyperactivity disorder
  • Research CNS disorders; Pain
  • No development reported Cardiovascular disorders

Most Recent Events

  • 06 Mar 2014 Early research in CNS disorders in USA (PO)
  • 24 May 2012 No development reported - Preclinical for CNS disorders in USA (PO)
  • 24 May 2012 No development reported for Cardiovascular disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top